alcoholic consumption group
Conditions
Interventions
NMN intervention group:Oral 600mg NMN tablet at timed daily
placebo control group:Oral 600 mg placebo daily
Sponsors
Zhejiang Chinese Medical University
Eligibility
Sex/Gender
Male
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age 30 to 60 years old, male; 2. Understand and voluntarily sign the informed consent; 3. Meet the clinical diagnostic criteria for fatty liver and the clinical diagnosis is fatty liver (magnetic resonance proton density fat fraction MRI-PDFF=10%); Serum ?-glutamyl transpeptidase (?-GT), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were slightly abnormal; 4. There was a history of drinking alcohol in the past, and the amount of ethanol in males was =40g/d (about 2 in ordinary liquor). 2), or a history of heavy drinking within 2 weeks, the equivalent of ethanol is more than 80g/d (about 4 taels of ordinary liquor).
Exclusion criteria
Exclusion criteria: 1. Combined with other hepatobiliary diseases, such as autoimmune liver disease, viral hepatitis, liver cirrhosis, etc.; 2. Combined with severe cardiovascular and cerebrovascular diseases, renal insufficiency; 3. Patients with cancer and other serious diseases; 4. Long-term use has been Drugs known to cause hepatic steatosis or steatohepatitis (such as amiodarone or tamoxifen); 5. Participate in other population intervention studies within one year or receive other non-study group treatments in the middle.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver fat content;nicotinamide adenine dinucleotide; | — |
Secondary
| Measure | Time frame |
|---|---|
| Alanine aminotransferase;Aspartate aminotransferase;?-glutamyl transpeptidase;total cholesterol;triglyceride;High-density lipoprotein cholesterol;Low-density lipoprotein cholesterol;N-methyl-2-pyridone- 5-carboxamide; | — |
Countries
China
Contacts
Public ContactLi Songtao
Outcome results
None listed